Martin Shkreli’s old company touts PhIII win, guns for accelerated approval

Nicole DeFeudis

Editor

Three months after rebranding to shed the last of its ties to convicted “Pharma Bro” Martin Shkreli, Travere Therapeutics is putting its best foot forward …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Martin Shkreli’s old company touts PhIII win, guns for accelerated approval

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

FDA OKs the first-ever self-administered vaccine, for flu

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

Mar­tin Shkre­li’s old com­pa­ny touts PhI­II win, guns for ac­cel­er­at­ed ap­proval

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Martin Shkreli’s old company touts PhIII win, guns for accelerated approval